Xeliri Regimen with Continuous Treatment of Bevacizumab is Well-Tolerated and Effective as Second-Line Chemotherapy in Patients with MCRC

Authors :: Junichi Sasaki
Yutaka J. Kawamura
Toshiki Rikiyama
Fumio Konishi
Shingo Tsujinaka
Koichi Suzuki
Takaharu Kato
Yuta Muto
Source :: Annals of Oncology. 24:iv107
Publication Year :: 2013
Publisher :: Elsevier BV, 2013.

Subjects :: Oncology
medicine.medical_specialty
Bevacizumab
business.industry
Hematology
Second line chemotherapy
Continuous treatment
Regimen
Internal medicine
Medicine
In patient
business
medicine.drug

Full Text Access

Tools